Physician profile
Mohammad Qamar
NPI 1104035955
$574.20
in general payments reported to CMS, 2019-2025
16 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $81.64 · 2021: $15.65 · 2022: $30.76 · 2023: $15.66 · 2024: $82.44 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $309.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.27 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $69.15 | 2019-2020 | |
| Genzyme Corporation | $41.33 | 2020-2025 | |
| Scpharmaceuticals INC. | $35.25 | 2024 | |
| Ardelyx, INC. | $34.21 | 2025 | Ibsrela |
| Horizon Therapeutics Plc | $32.85 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $32.50 | 2023-2025 | Velphoro, Velphoro |
| Takeda Pharmaceuticals U.S.A., INC. | $31.20 | 2024 | Livtencity |
| E.R. Squibb & Sons, L.L.C. | $28.96 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $28.77 | 2019 | |
| Calliditas Therapeutics US INC. | $28.41 | 2025 | Tarpeyo |
| Shire North American Group INC | $22.34 | 2019 | |
| Baxter Healthcare | $19.62 | 2019 | |
| Nxstage Medical, INC. | $18.70 | 2025 | Liberty Select Cycler, Nxstage System One |
| Travere Therapeutics, INC. | $15.99 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Qamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.